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To determine when a change in serial measurements of prothrombin time in patients receiving oral anticoagulant therapy (ACT) is a statistically significant biological change necessitating dose adjustment, one must know the size of the "critical difference" in statistical terms (i.e., probabilities). In a cohort of 32 ACT patients at pharmacological steady-state, we studied the within-subject total variation of prothrombin time, expressed as Inter- However, only data on within-subject variation of PT in healthy subjects have been reported, and these are not directly applicable to the therapeutic situation of ACT.
Accordingly, we investigated total variation of INR from ACT patients as the basis for estimating critical differences of serial INR values at different intensities of ACT.
Materials and Methods

Design of the Study
The procedures followed in this study were in accordance with the second Declaration of Helsinki (amended in 1989 
where CV denotes the total variation of the analyte, and Z is the Z-score, the number of SDs appropriate for the level of probability selected to indicate significance. For P 0.05, commonly used in clinical medicine, Z is 1.96 for a two-sided (any change) critical difference and 1.65 for a one-sided (rise or fall) difference (10).
Results Table 1 lists the estimates of total variation during 6 months.
The mean variation 
